Biocon Limited
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
What Biocon files
- Updates91
- Others75
- Important67
- Investor Meet62
- Board Meeting23
- PPTs9
Biocon's subsidiary received marketing approval for its pegfilgrastim biosimilar in Japan. This strengthens Biocon's portfolio there. Sandoz K.K. will exclusively promote and distribute the product, expanding patient access to high-quality, affordable medications.
Biocon's US subsidiary secured FDA approval for Yesintek® (ustekinumab-kfce) single-dose autoinjectors. This new delivery format expands patient treatment options for autoimmune diseases, significantly strengthening Biocon's immunology presence in the US market.
Biocon's Canadian subsidiary secured Health Canada approval for Yesintek® (ustekinumab) Autoinjector Pen. This new format strengthens Biocon's immunology portfolio in Canada, providing a unique patient option for autoimmune conditions like psoriasis and Crohn's disease, boosting market access.
Biocon Malaysia received EMA approval for its new insulin fill-finish unit. This expands manufacturing capacity for Semglee® (insulin glargine), enabling European market supplies to commence in Q2FY27.
Biocon Pharma, a subsidiary, received Health Canada approval for Micafungin for injection (50/100 mg), used for Candidiasis. This approval expands Biocon's generics portfolio, enhancing its market position in biosimilars and generics.